Abstract

Abstract Background Bladder cancer is still a prevalent, heterogeneous, and challenging disease. Most cases are non-muscle invasive and carry a significant risk of recurrence and progression despite current advances in therapeutic options. Main c-MET and HER2 belong to the receptor tyrosine kinase family, which has been intensively studied in cancer. Both receptors are upregulated in bladder cancer and have been connected to tumor development and progression by activating a variety of signaling pathways that control proliferation, migration, and metastasis. C-MET and HER2 are indicators of aggressive bladder cancer and possible therapeutic targets. This review will investigate the contributions of c-MET and HER2 in the genesis and progression of bladder cancer, the implications for therapy and ongoing research in this field. Conclusion Targeting c-MET and HER2 together, either as monotherapy or combined therapy, might become promising in managing aggressive bladder cancer.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.